Nycomed's story is one of rapid growth and strategic partnerships, ultimately leading to its acquisition by Takeda in 2011. The company was founded in 1874 in Norway, and by the early 2000s, it had expanded into a global player in the pharmaceutical industry.
Nycomed's aggressive expansion strategy involved acquiring several smaller companies, including Altana Pharma in 2007. This acquisition significantly boosted Nycomed's presence in the European market.
Nycomed's growth was also fueled by its focus on developing and commercializing generic and branded pharmaceuticals. The company's portfolio included a range of products, from cardiovascular treatments to respiratory medications.
Take a look at this: How to Find Growth Rate of Company
Takeda Acquires Nycomed
Takeda Pharmaceutical has acquired Nycomed, a Swiss pharmaceutical company, for $13.7 billion.
The acquisition is the largest ever by a Japanese drug company, and it will increase Takeda's presence in European and emerging markets.
Takeda's CEO, Yasuchika Hasegawa, stated that Nycomed enables Takeda to maximize the value of its portfolio and gives it an immediate strong presence in high-growth emerging markets.
If this caught your attention, see: Takeda Pharmaceutical Company
Nycomed has sales in its most recent fiscal year of about $17.3 billion, and it gets almost 40% of its sales from emerging markets.
The acquisition includes the roflumilast franchise, a treatment for chronic obstructive pulmonary disease, which Takeda expects will be a major source of revenue growth.
Takeda expects the acquisition to increase its annual revenue by 30%.
The boards of directors of Takeda and Nycomed have agreed to the transaction, as have the shareholders of Nycomed.
The deal is expected to close within 90 to 120 days, subject to antitrust approval.
Nycomed will become a subsidiary of Takeda upon closing.
The acquisition is part of Takeda's effort to become a bigger player outside Japan and to offset the 2012 U.S. patent expiration for its leading product, the diabetes drug Actos.
Takeda has been aggressive in expanding outside Japan, and other Japanese pharmaceutical companies have also been making moves.
The acquisition is the second major deal for Takeda after it bought U.S. cancer drug specialist Millennium Pharmaceuticals in 2008 for about $8.8 billion.
Nycomed's top product is Pantoprazole for heartburn, a field that Takeda knows well with its own Prevacid, a former blockbuster heartburn drug that has now lost patent protection.
Explore further: Credit Derivatives Product Company
Research and Development
Nycomed was a company that valued research and development, and it showed through its various activities.
The company had internal research and development activities, which allowed it to stay ahead of the curve in its industry.
Nycomed also engaged in publicly funded collaborative research projects with other industrial and academic partners, such as the InnoMed PredTox for non-clinical safety assessment.
These collaborative efforts helped Nycomed leverage the expertise of others and drive innovation in the field.
Explore further: Class B Shares Private Company
Featured Images: pexels.com
